News

Oppenheimer Raises Price Target for Trevi Therapeutics by $3
Oppenheimer maintained its Outperform rating on Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares and lifted the price target ...
Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results
Oppenheimer increased its price target for Trevi Therapeutics Inc. (NASDAQ:TRVI) to $23 from $20, while maintaining an ...